---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-25-000069"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:22:53.727556+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics Q3 2025 net loss $16.7M; VIZZ launch with 5K+ prescriptions in October

## Summary
- Net loss $16.7M ($0.59/share) vs $10.2M in Q3 2024; R&D spend down to $3.8M.
- SG&A expenses surged to $27.6M ($6.5M Q3 2024) from commercial launch infrastructure.
- Pro forma cash $324M after $123.5M ATM raise in Oct 2025, extending runway to post-launch cash flow positive.
- VIZZ (aceclidine) launched Oct 2025 with >2,500 unique prescribers and >5,000 prescriptions filled through Oct.
- Partnered with Sarah Jessica Parker for DTC campaign starting Q1 2026; Canada deal with Théa worth >$70M in milestones.

## SEC filing metadata
- accession: 0001815776-25-000069
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000069/0001815776-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000069/lenz-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-25-000069
- JSON: https://secwatch.observer/filing/0001815776-25-000069.json
- Plain text: https://secwatch.observer/filing/0001815776-25-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.